<DOC>
	<DOCNO>NCT00769587</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth systemic mastocytosis block blood flow disease . PURPOSE : This phase II trial study well thalidomide work treat patient relapse progressive systemic mastocytosis .</brief_summary>
	<brief_title>Thalidomide Treating Patients With Relapsed Progressive Systemic Mastocytosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate 6 month patient systemic mastocytosis treat thalidomide . Secondary - Determine tolerability drug patient . OUTLINE : This multicenter study . Patients receive oral thalidomide daily 6 month absence disease progression .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis systemic mastocytosis Aggressive borderline ( smolder ) disease ( first line ) Relapsed progressive disease Measurable evaluable disease Presence cKit D816V mutation skin , spine , infiltrated organs No nonsymptomatic mastocytosis PATIENT CHARACTERISTICS : Life expectancy &gt; 3 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month prior , , first menstrual cycle completion study treatment Bilirubin &lt; 2 time normal ( unrelated disease ) Liver enzymes &lt; 2 time normal ( unrelated disease ) Creatinine â‰¤ 300 mmol/L No central peripheral neuropathy lead psychiatric concern No HIV positivity No active infection serious underlying illness would preclude treatment No history thromboembolism deep vein thrombosis No geographical , social , psychological reason prevent medical monitoring PRIOR CONCURRENT THERAPY : More 4 week since prior antitumor therapy ( e.g. , chemotherapy , radiotherapy ) No concurrent treatment specific disease No concurrent participation another experimental drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>aggressive systemic mastocytosis</keyword>
	<keyword>smolder systemic mastocytosis</keyword>
</DOC>